Clinical Trials Browser

Phase 2 × HER2-positive Solid Tumor × zirconium-89-trastuzumab × Clear all

NCT04757090 2021-12-23

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

Phase 2 Withdrawn

Other solid neoplasm

HER2-positive Solid Tumor